New Jersey Mental Health Outpatient Licensing

Author: A. Ant, CADC-II, Licensing & Accreditation Expert

Disclaimer: This content is provided for general informational purposes only and should not be construed as legal, regulatory, or licensing advice. Requirements change frequently. Consult qualified professionals for guidance specific to your situation.

Apply now: DOH Division of Certificate of Need and Licensing (CN&L) | Questions: cnandlicensingrequests@doh.nj.gov

Since April 6, 2026, an outpatient mental health clinic in New Jersey is licensed under N.J.A.C. 8:43K, the Manual of Standards for Licensure of Outpatient and Integrated Care Facilities. The license is issued by the Department of Health, Division of Certificate of Need and Licensing (CN&L), not DMHAS. Before that date the licensing chapter for these clinics was N.J.A.C. 8:121 (which DHS ran as 10:190 before it moved to DOH), and the 8:43K rulemaking amended 8:121 to take outpatient and partial care programs out of it.

One Licensing Chapter, With DMHAS Service Standards on Top

An outpatient mental health clinic no longer picks between chapters. A clinic offering only mental health care applies under 8:43K, and so does a site that adds substance use disorder treatment, an opioid treatment program or primary care, which can now share one integrated license instead of carrying several. The service mix still shapes the work, because it decides which program standards you write your policies to. DHS’s N.J.A.C. 10:36, Behavioral Health Program Service Standards, applies to all facilities DOH licenses under 8:43K to provide adult outpatient behavioral health care, and the program types it covers are outpatient mental health and addiction care, partial care (mental health or addiction), intensive outpatient addiction treatment and opioid treatment programs.

Licensing Sits at DOH, but DMHAS Still Has a Role

Sending the application to DMHAS instead of DOH is still an easy mistake to make, and a state that moved the same division twice in two years deserves some of the blame. DMHAS went to the Department of Health, mental health and SUD facility licensing with it, under Reorganization Plan No. 001-2017, effective August 28, 2017. Reorganization Plan No. 001-2018 took effect August 20, 2018 and returned only DMHAS to Human Services; licensing and inspection of those facilities stayed at DOH. DMHAS is New Jersey’s Single State Agency for substance use and its State Mental Health Authority, and it still holds mental health and SUD policy and regulatory authority. It doesn’t issue your license, but you can’t ignore it either: under N.J.A.C. 10:36-3.1(a)1 a program must “Have a contract or affiliation agreement with the DMHAS.”

No Certificate of Need for Outpatient Mental Health Care

N.J.S.A. 26:2H-7a names “Mental health services which are non-bed related outpatient services” among the services exempt from the certificate of need requirement, so a clinic with no beds stays outside CON review. Beds change that. DOH’s Certificate of Need page lists psychiatric beds under full review, which matters only if an outpatient plan later grows an inpatient unit.

Ketamine and Spravato at an 8:43K Outpatient Clinic

The 8:43K adoption notice we read says nothing about ketamine or esketamine. What it does say, in DOH’s response to Comment 17, is that a facility wanting to provide services beyond the one it holds “will have to apply to add the new service(s).” A clinic whose psychiatrist already manages medications may see ketamine as part of that existing work, but DOH could view an infusion or Spravato program as something new. We’d write to Integrated.License@doh.nj.gov, the 8:43K contact in the DMHAS overview listed below, and get a written answer before buying equipment.

There is a second route. New Jersey’s facility licensing statute carves out “services provided by a physician in his private practice,” subject to exceptions it lists (N.J.S.A. 26:2H-2(b)). In our reading, that lets a psychiatrist’s own practice offer ketamine or Spravato next door to the licensed clinic without a DOH facility license of its own. The ownership limits on that practice are covered in the ketamine section of New Jersey Drug and Alcohol Outpatient Treatment Licensing.

Whichever entity holds the drug, it is Schedule III (21 CFR 1308.13(c)(7)). The Drug Control Unit’s FAQ says even “practitioners who simply prescribe controlled dangerous substances” need a New Jersey CDS registration, each extra location where you keep a CDS stock needs its own, and the state address “MUST be the same as the address used for the DEA registration.” DEA also registers by location (21 CFR 1301.12(a)). For an APN, N.J.S.A. 45:11-49(c) leaves it to the joint protocols with the collaborating physician to say whether “prior consultation” comes before the APN initiates a controlled dangerous substance prescription, so name ketamine in those protocols.

The PMP duty is narrower here than many expect. Ketamine is Schedule III and neither an opioid nor a benzodiazepine, and for drugs in that group N.J.S.A. 45:1-46.1 ties the first-prescription lookup to a “reasonable belief that the person may be seeking a controlled dangerous substance” for something other than treating an existing condition. Subsection b.(3) also takes “a practitioner administering a controlled dangerous substance directly to a patient” out of those requirements. Our reading is that in-clinic doses fit that exception, though we’d still check the PMP at intake.

Two more limits shape the protocol. In the Board of Medical Examiners’ office rules, “anesthesia services” means giving an anesthetic agent with the purpose of creating moderate sedation, regional anesthesia or general anesthesia (N.J.A.C. 13:35-4A.3), and that brings in the subchapter’s office anesthesia standards, so the written protocol should state the intended depth of sedation and whether it reaches that level. Spravato is restricted by its Medication Guide to REMS-certified healthcare settings, where the patient stays under provider monitoring for a minimum of 2 hours.

Staffing an Outpatient Mental Health Program

A small outpatient program typically needs a clinical director and two to three clinicians, and New Jersey’s associate-level staffing tier is what keeps that number manageable. In the BLS category for substance abuse, behavioral disorder, and mental health counselors, the New Jersey median is $64,710 a year (BLS OEWS, May 2024), compared with roughly $59,350 nationwide. For a clinical director with two to three clinicians, expect clinical payroll of $250,000 to $340,000 a year before benefits, which the right staffing mix keeps within reach. Mental health clinicians are licensed through their own respective New Jersey boards, and many practices pair a fully licensed clinical director with associate-level clinicians working toward independent licensure under that director’s supervision, an arrangement that lowers payroll and lets those clinicians finish their hours in-house. A specific staffing plan waits on your service mix and projected census.

Putting Together the 8:43K Application

The 8:43K application is DOH form CN-7, sent in with the applicable fees. DMHAS’s 2026 overview of the integrated license gives Integrated.License@doh.nj.gov as the contact for 8:43K questions and says full applications could expect to be assigned beginning July 1, 2026. CN&L’s intake and renewals desk is at cnandlicensingrequests@doh.nj.gov. Inside CN&L, the Technical Assistant Unit processes applications and the Routine Unit does inspections. Write your policies and procedures to 8:43K and 10:36, and have the DMHAS contract or affiliation agreement underway before you file.

What Delays New Jersey Outpatient Mental Health Applications

In our experience two problems account for most of the delays. The first is paperwork built for the old rules. Per the DMHAS overview, applications received between April 6 and May 1, 2026 were to be sent back for a new CN-7 and policies revised to match 8:43K, and policies written around 10:37E or the old 8:121 outpatient provisions need the same rework. The second is treating DMHAS as either the licensor or as irrelevant: the license comes from CN&L, but the DMHAS agreement under 10:36 still has to be in place.

Frequently Asked Questions

Getting a New Jersey outpatient mental health program ready for an 8:43K application? Reach out here.

Sources

• NJ Department of Health, N.J.A.C. 8:43K notice of adoption (effective April 6, 2026): Manual of Standards for Licensure of Outpatient and Integrated Care Facilities (checked October 8, 2026)
• NJ Department of Health, N.J.A.C. 8:43K notice of proposal, 57 N.J.R. 743(a) (8:121 amendments, Reorganization Plans 001-2017 and 001-2018): 8:43K proposal (checked October 8, 2026)
• NJ Department of Human Services, N.J.A.C. 10:36 adoption and repeal of 10:37E, 58 N.J.R. 1382(a): Behavioral Health Program Service Standards (checked October 8, 2026)
• NJ DMHAS: New Jersey Integrated License and Regulatory Scheme overview (2026) (checked October 8, 2026)
• NJ DMHAS: Division of Mental Health and Addiction Services home page (checked October 8, 2026)
• N.J.S.A. 26:2H-7a, certificate of need exemptions (Justia mirror of official text, 2025 version): 26:2H-7a (checked October 8, 2026)
• NJ Department of Health: Certificate of Need (checked October 8, 2026)
• NJ Department of Health: Health Facilities contacts (checked October 8, 2026)
• NJ Department of Health, form CN-7: Application for New or Amended Acute Care Facility License (checked October 8, 2026)
• N.J.S.A. 26:2H-2 (Justia mirror of official text, 2025 version): Definitions, physician private practice exclusion (checked October 9, 2026)
• NJ Division of Consumer Affairs, Drug Control Unit: CDS registration FAQ (checked October 9, 2026)
• N.J.S.A. 45:1-46.1 (Justia mirror of official text, 2025 version): Prescription monitoring program access (checked October 9, 2026)
• N.J.S.A. 45:11-49 (Justia mirror of official text): Advanced practice nurse prescribing and joint protocols (checked October 9, 2026)
• N.J.A.C. 13:35-4A.3, via Cornell LII: Office anesthesia definitions (checked October 9, 2026)
• 21 CFR 1308.13(c)(7), via Cornell LII: Ketamine in Schedule III (checked October 9, 2026)
• 21 CFR 1301.12(a), via Cornell LII: Separate DEA registration for each location (checked October 9, 2026)
• FDA: Spravato prescribing information and Medication Guide (REMS, two-hour monitoring) (checked October 9, 2026)